$MPLT

MapLight Therapeutics, Inc.

MapLight Therapeutics is a clinical-stage biopharmaceutical company developing treatments for patients with central nervous system disorders. Its discovery platform uses optogenetics, single-cell transcriptomics and STARmap to identify disease-related neural circuits and drug targets. MapLight retains global development and commercial rights to its programs. Its lead candidate, ML-007C-MA, combines an M1/M4 muscarinic agonist with a peripherally acting anticholinergic and is being evaluated for schizophrenia and Alzheimer’s disease psychosis. ML-004, an immediate-release and extended-release formulation of zolmitriptan, is in development for social communication deficits and/or irritability in autism spectrum disorder. The company is also advancing preclinical programs ML-009, ML-055 and ML-021. MapLight is headquartered in Redwood City, California.

AlphAI earnings readQ3 FY2026 · NOV 16MapLight reports Q3 2026 net loss of $51.6 million, with $463.4 million in cash and ZEPHYR-2 Phase 3 planning underwayVerdict: mixed

Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.

2
3
2

No SEC Form 4 filings for $MPLT in the last 30 days.

See all $MPLT insider activity →

MapLight Therapeutics, Inc. (MPLT): Entry into a Material Definitive Agreement

MapLight Therapeutics, Inc. (MPLT) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry Into A Material Definitive Agreement. On November 16, 2026, MapLight Therapeutics, Inc. (the “ Company ”) entered into a Sales Agreement (the “ Agreement ”) with Leerink Partners LLC (the “ Agent ”), pursuant to which the Company from time to time may offer and se

MapLight Moves Toward Phase 3 Schizophrenia Trial; VISTA Study Enrollment Continues

MapLight Therapeutics (MPLT) reported a Q3 2026 net loss of $51.6M, up from $29.4M YoY. The company plans a Phase 3 trial for ML-007C-MA in schizophrenia and continues enrollment in a Phase 2 trial for Alzheimer's disease psychosis. MPLT has $463.4M in cash and expects funds to last through 2028. The stock closed at $7.25, up 2.55%.

MPLT sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 7 news stories mentioning MPLT (MapLight Therapeutics, Inc.). Coverage has been balanced: 2 bullish, 3 neutral, and 2 bearish.

Recent MPLT coverage spans corporate actions, insider activity and earnings.

What's driving MPLT

  • Canaccord Genuity reaffirmed its Buy rating and $21 price target for MapLight Therapeutics, implying a 204.3% upside from the Nov 16 close of $6.90.

    tradingview.com · Nov 17, 2026

  • The ATM creates an ongoing dilution overhang risk, but also provides flexible funding capacity.

    SEC EDGAR 8-K · Nov 16, 2026

  • Positive trial initiation and sizable capital raise could lift the stock if data are favorable.

    rttnews.com · Nov 16, 2026

  • Strong cash position and clear trial milestones may reduce financing risk and support upside, but a $51.6M net loss adds downside pressure.

    SEC EDGAR 8-K · Nov 16, 2026

  • The insider sale may signal personal liquidity needs or lack of confidence, but the amount is modest.

    SEC EDGAR · Oct 16, 2026

AlphAI scores every news story that mentions MPLT with an AI model for sentiment and relevance, and aggregates insider trades from MapLight Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $MPLT

Score
$MPLTMedOffering· $100M · proposed

MapLight Therapeutics, Inc. (MPLT): Entry into a Material Definitive Agreement

MapLight Therapeutics, Inc. (MPLT) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry Into A Material Definitive Agreement. On November 16, 2026, MapLight Therapeutics, Inc. (the “ Company ”) entered into a Sales Agreement (the “ Agreement ”) with Leerink Partners LLC (the “ Agent ”), pursuant to which the Company from time to time may offer and se

$MPLTHighEarnings

MapLight Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

MapLight Therapeutics, Inc. (MPLT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 MapLight Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update Planning underway for ZEPHYR-2, the confirmatory Phase 3 trial of ML-007C-MA in schizophrenia, with topline results expected in the second half 2027 Enrollment ongoing in

$MPLTMedEarnings

MapLight Therapeutics, Inc. (MPLT): Reported positive results from the potentially registrational Phase 2 ZEPHYR trial of ML-007C-MA in schizophrenia, supporting advancement into a Phase 3…

MapLight Therapeutics, Inc. (MPLT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Reported positive results from the potentially registrational Phase 2 ZEPHYR trial of ML-007C-MA in schizophrenia, supporting advancement into a Phase 3 ZEPHYR-2 trial Continued advancement of ML-007C-MA in ADP, with enrollment ongoing in the Phase 2 VISTA trial and

MapLight Therapeutics, Inc.: MapLight Therapeutics Announces $150 Million Private Placement Financing

MapLight Therapeutics (Nasdaq: MPLT) announced a $150 million PIPE private placement. It will sell 9,197,887 common shares at $11.38 and pre-funded warrants for up to 3,983,168 shares at $11.3799, with an exercise price of $0.0001. Proceeds will fund ML-007C-MA (VISTA Phase 2 and ZEPHYR-2 Phase 3) and working capital. Expected close Aug. 14, 2026.

Related tickers